A Phase 4 interventional study of gabapentin 600 mg and gabapentin 1200 mg in Abuse Potential, sponsored by Viatris Specialty LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Viatris Specialty LLC (part of Viatris Inc.) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6 treatment, 6-period crossover single-dose, Williams square design study in healthy male and/or female adult, non-drug-dependent recreational opioid users.
The study includes Screening, a Qualification Phase consisting of a Naloxone Challenge and Drug Discrimination crossover study, a Treatment Phase and Follow-up. Following successful completion of the Qualification Phase the participants will be enrolled in the Treatment phase. The Treatment Phase is a randomized, double-blind, double dummy, placebo- and active controlled, 6 treatment, 10-sequence, 6 period crossover, single-dose, Williams square design study in healthy male and/or female adult, non drug-dependent recreational users. On Day 1 of each of the Treatment Phase 6 periods, which will be separated by a washout of at least 14 days, participants will receive an oral dose of either gabapentin 600 mg or 1200 mg alone, or concomitantly with a 20 mg dose of oxycodone HCl or 20 mg monotherapy of oxycodone HCl or a placebo. Study treatments will be administered under fasted conditions (overnight fast and no food until 4 hours after dosing). Water will be allowed without restriction until 1 hour prior to dosing and 1 hour after dosing.
Viatris Specialty LLC is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: gabapentin 600 mg
Drug: gabapentin 1200 mg
Drug: gabapentin 600 mg and oxycodone HCl 20 mg
Drug: gabapentin 1200 mg and oxycodone HCl 20 mg
Drug: oxycodone HCl 20 mg
Drug: placebo
Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl
Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl
Drug page: Gabapentin
Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg
Drug page: Gabapentin
Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg
Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin
Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl
Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax).
Drug liking assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
Time frame: up to 48 hours after treatments
Bipolar VAS for "Drug Liking" - Time to Maximum Effect (TEmax)
Time after dosing when the maximum effect for Drug Liking VAS is reached
Time frame: up to 48 hours after treatments
Bipolar VAS for "Drug Liking": Area Under the Effect Curve From Time 0 to the Last Available Data (AUEClast)
Area under the effect-time profile from time 0 to the time of the last available data for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
Time frame: Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 1 Hour (AUEC1)
Area under the effect-time profile from time 0 to 1 hour post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
Time frame: Up to 1 hour post-dose (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, and 1 hour)
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 2 Hours (AUEC2)
Area under the effect-time profile from time 0 to 2 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
Time frame: Up to 2 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, and 2 hours)
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 3 Hours (AUEC3)
Area under the effect-time profile from time 0 to 3 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
Time frame: up to 3 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, and 3 hours)
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 4 Hours (AUEC4)
Area under the effect-time profile from time 0 to 4 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
Time frame: Up to 4 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, and 4 hours)
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 8 Hours (AUEC8)
Area under the effect-time profile from time 0 to 8 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
Time frame: Up to 8 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours)
Unipolar VAS for "High" - Maximum Effect (Emax)
Maximum effect on the 100 mm visual analog scale for the question "I am feeling high" where 0 = "not at all" and 100 = "extremely"
Time frame: up to 48 hours after treatments
Unipolar VAS for "High": Time to Maximum Effect (TEmax)
Time after dosing when the maximum effect for "High" VAS is reached
Time frame: up to 48 hours after treatments
Area Under the Effect Curve for "High" VAS (AUEClast)
Area under the effect-time profile from time 0 to the time of the last available data for the "High" visual analog scale which measures on a 100 mm visual analog scale the subject's response to the question "I am feeling high" where 0 = "not at all" and 100 ="extremely"
Time frame: Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Bipolar VAS for "Take Drug Again"
100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "I would take this drug again" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included
Time frame: Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 24, 36, and 48 hours)
Bipolar VAS for "Overall Drug Liking"
100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "Overall, my liking for this drug is" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included
Time frame: Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 24, 36, and 48 hours)
Unipolar VAS for "Good Drug Effect"
100 mm visual analog scale for the question "At this moment, I can feel good drug effects" where 0 = "not at all" and 100 = "extremely"
Time frame: up to 48 hours after treatments
Unipolar VAS for "Bad Drug Effect"
100 mm visual analog scale for the question "At this moment, I can feel bad drug effects" where 0 = "not at all" and 100 = "extremely"
Time frame: up to 48 hours after treatments
Unipolar VAS for "Any Drug Effect"
100 mm visual analog scale for the question "At this moment, I can feel any drug effects" where 0 = "not at all" and 100 = "extremely"
Time frame: up to 48 hours after treatments
Cmax of Gabapentin
Maximum plasma concentration of gabapentin
Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Tmax of Gabapentin
Time when the maximum concentration of gabapentin is reached
Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
AUCinf of Gabapentin
Area under the plasma concentration/time curve from time 0 extrapolated to infinity time of gabapentin
Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
AUClast of Gabapentin
Area under the plasma concentration/time profile from time 0 to the time of the last quantifiable concentration of gabapentin
Time frame: Up to 48 hours after treatment (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Half-life (t½) of Gabapentin
Half-life (t½) of gabapentin
Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Cmax of Oxycodone
Maximum plasma concentration of Oxycodone
Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Tmax of Oxycodone
Time when the maximum concentration of Oxycodone is reached
Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
AUCinf of Oxycodone
Area under the plasma concentration/time curve from time 0 extrapolated to infinity time of Oxycodone
Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
AUClast of Oxycodone
Area under the plasma concentration/time profile from time 0 to the time of the last quantifiable concentration of Oxycodone
Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Half-life (t½) of Oxycodone
Half-life (t½) of Oxycodone
Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 |
|---|---|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 | 9 | 9 |
| Completed | 8 | 8 | 9 | 9 | 8 | 8 |
| Not completed | 1 | 1 | 0 | 0 | 1 | 1 |
Drug liking assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
| Score on a 100 mm scale | Placebo | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax). | 54.89 ± 2.116 | 87.40 ± 3.156 | 57.89 ± 3.142 | 63.62 ± 3.334 | 88.43 ± 3.216 | 92.17 ± 2.713 |
Time after dosing when the maximum effect for Drug Liking VAS is reached
| hours | Placebo Single Dose | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Bipolar VAS for "Drug Liking" - Time to Maximum Effect (TEmax) | 0.25 (0.2 to 24.0) | 1.00 (0.2 to 3.5) | 0.25 (0.25 to 2.5) | 0.28 (0.1 to 12.1) | 1.00 (0.2 to 12.0) | 1.50 (0.2 to 4.0) |
Area under the effect-time profile from time 0 to the time of the last available data for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
| units on a scale * hour | Placebo Single Dose | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Bipolar VAS for "Drug Liking": Area Under the Effect Curve From Time 0 to the Last Available Data (AUEClast) | 2394.21 ± 65.274 | 2661.43 ± 84.274 | 2422.37 ± 85.855 | 2444.4 ± 83.580 | 2744.86 ± 76.342 | 2759.57 ± 74.589 |
Area under the effect-time profile from time 0 to 1 hour post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
| units on a scale * hour | Placebo | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 1 Hour (AUEC1) | 50.17 ± 0.317 | 58.86 ± 1.478 | 51.28 ± 1.440 | 50.61 ± 0.568 | 57.02 ± 1.771 | 55.76 ± 1.390 |
Area under the effect-time profile from time 0 to 2 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
| units on a scale * hour | Placebo | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 2 Hours (AUEC2) | 102.62 ± 1.791 | 140.44 ± 4.434 | 105.20 ± 4.017 | 107.19 ± 2.449 | 138.72 ± 4.340 | 133.84 ± 4.010 |
Area under the effect-time profile from time 0 to 3 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
| units on a scale * hour | Placebo | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 3 Hours (AUEC3) | 155.48 ± 3.651 | 219.31 ± 7.614 | 161.07 ± 6.535 | 164.03 ± 4.819 | 223.22 ± 7.326 | 214.99 ± 6.567 |
Area under the effect-time profile from time 0 to 4 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
| units on a scale * hour | Placebo | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 4 Hours (AUEC4) | 208.32 ± 5.171 | 294.28 ± 10.329 | 214.53 ± 8.878 | 220.08 ± 6.896 | 305.08 ± 10.423 | 293.99 ± 8.810 |
Area under the effect-time profile from time 0 to 8 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"
| units on a scale * hour | Placebo | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 8 Hours (AUEC8) | 411.58 ± 12.224 | 551.53 ± 19.517 | 421.12 ± 17.144 | 438.30 ± 13.862 | 599.96 ± 22.312 | 574.98 ± 18.952 |
Maximum effect on the 100 mm visual analog scale for the question "I am feeling high" where 0 = "not at all" and 100 = "extremely"
| Score on a 100 mm scale | Placebo Single Dose | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Unipolar VAS for "High" - Maximum Effect (Emax) | 13.45 ± 4.854 | 77.36 ± 5.8160 | 28.61 ± 6.551 | 25.21 ± 6.412 | 81.86 ± 5.620 | 88.74 ± 4.210 |
Time after dosing when the maximum effect for "High" VAS is reached
| hours | Placebo Single Dose | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Unipolar VAS for "High": Time to Maximum Effect (TEmax) | 0.25 (0.2 to 8.0) | 1.00 (0.3 to 4.0) | 0.26 (0.2 to 8.0) | 0.27 (0.1 to 144.9) | 1.00 (0.2 to 48.1) | 1.50 (0.2 to 4.1) |
Area under the effect-time profile from time 0 to the time of the last available data for the "High" visual analog scale which measures on a 100 mm visual analog scale the subject's response to the question "I am feeling high" where 0 = "not at all" and 100 ="extremely"
| units on a scale * hour | Placebo Single Dose | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Area Under the Effect Curve for "High" VAS (AUEClast) | 33.45 ± 14.904 | 321.75 ± 46.346 | 86.41 ± 31.541 | 123.74 ± 50.060 | 512.08 ± 66.299 | 425.01 ± 52.651 |
100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "I would take this drug again" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included
| Score on a 100 mm scale | Placebo Single Dose | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Bipolar VAS for "Take Drug Again" | 53.43 ± 2.928 | 72.16 ± 2.918 | 55.19 ± 2.942 | 58.05 ± 2.935 | 79.16 ± 2.940 | 77.85 ± 2.910 |
100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "Overall, my liking for this drug is" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included
| Score on a 100 mm scale | Placebo Single Dose | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Bipolar VAS for "Overall Drug Liking" | 51.75 ± 2.895 | 72.06 ± 2.886 | 54.40 ± 2.909 | 58.25 ± 2.902 | 75.90 ± 2.907 | 79.94 ± 2.878 |
100 mm visual analog scale for the question "At this moment, I can feel good drug effects" where 0 = "not at all" and 100 = "extremely"
| Score on a 100 mm scale | Placebo | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Unipolar VAS for "Good Drug Effect" | 2.54 ± 2.123 | 27.91 ± 2.117 | 6.13 ± 2.117 | 8.73 ± 2.120 | 34.72 ± 2.119 | 32.71 ± 2.113 |
100 mm visual analog scale for the question "At this moment, I can feel bad drug effects" where 0 = "not at all" and 100 = "extremely"
| Score on a 100 mm scale | Placebo | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Unipolar VAS for "Bad Drug Effect" | 0.19 ± 1.211 | 4.41 ± 1.209 | 0.82 ± 1.209 | 0.97 ± 1.210 | 4.10 ± 1.210 | 3.41 ± 1.207 |
100 mm visual analog scale for the question "At this moment, I can feel any drug effects" where 0 = "not at all" and 100 = "extremely"
| Score on a 100 mm scale | Placebo | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| Unipolar VAS for "Any Drug Effect" | 3.77 ± 2.167 | 28.46 ± 2.161 | 6.63 ± 2.162 | 7.88 ± 2.164 | 34.34 ± 2.163 | 33.76 ± 2.158 |
Maximum plasma concentration of gabapentin
| micrograms/milliliter | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|
| Cmax of Gabapentin | 4.16 ± 1.422 | 6.07 ± 1.951 | 4.17 ± 1.121 | 6.18 ± 1.443 |
Time when the maximum concentration of gabapentin is reached
| Hours | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|
| Tmax of Gabapentin | 3.13 (1.2 to 6.1) | 3.13 (1.6 to 6.1) | 3.13 (1.2 to 8.1) | 3.13 (1.2 to 8.2) |
Area under the plasma concentration/time curve from time 0 extrapolated to infinity time of gabapentin
| micrograms*hour/milliliter | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|
| AUCinf of Gabapentin | 41.42 ± 11.798 | 65.38 ± 18.854 | 48.58 ± 12.009 | 75.18 ± 18.431 |
Area under the plasma concentration/time profile from time 0 to the time of the last quantifiable concentration of gabapentin
| micrograms*hour/milliliter | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|
| AUClast of Gabapentin | 39.76 ± 11.856 | 61.42 ± 19.900 | 47.31 ± 12.142 | 72.73 ± 17.781 |
Half-life (t½) of gabapentin
| Hours | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|
| Half-life (t½) of Gabapentin | 9.14 ± 10.846 | 10.62 ± 7.674 | 8.20 ± 3.551 | 9.19 ± 3.596 |
Maximum plasma concentration of Oxycodone
| nanograms/milliliter | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|
| Cmax of Oxycodone | 44.92 ± 17.336 | 43.82 ± 14.144 | 40.79 ± 14.809 |
Time when the maximum concentration of Oxycodone is reached
| hours | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|
| Tmax of Oxycodone | 1.15 (0.6 to 8.1) | 1.15 (0.6 to 5.9) | 1.63 (0.6 to 3.6) |
Area under the plasma concentration/time curve from time 0 extrapolated to infinity time of Oxycodone
| nanograms*hour/milliliter | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|
| AUCinf of Oxycodone | 233.29 ± 64.369 | 228.40 ± 71.854 | 234.94 ± 77.115 |
Area under the plasma concentration/time profile from time 0 to the time of the last quantifiable concentration of Oxycodone
| nanograms*hour/milliliter | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|
| AUClast of Oxycodone | 229.31 ± 64.935 | 224.79 ± 71.748 | 234.65 ± 80.068 |
Half-life (t½) of Oxycodone
| hours | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|
| Half-life (t½) of Oxycodone | 4.12 (2.6 to 6.2) | 3.84 (2.2 to 6.1) | 3.90 (2.4 to 10.7) |
Collected over During the entire Treatment Phase of the study, which encompassed the time interval from admission of the subject to their first Treatment Period until 28 days after study drug dosing in their last (6th) Treatment Period, including the washout in between Treatment Periods. The total duration of the Treatment Phase for each subject was dependent on visit scheduling and whether the subject completed all 6 treatment periods, and it lasted up to approximately 13 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/53 (0%) | 0/53 (0%) | 0/53 (0%) |
| Oxycodone HCl 20 mg Single Dose | 0/52 (0%) | 0/52 (0%) | 4/52 (7.7%) |
| Gabapentin 600 mg Single Dose | 0/51 (0%) | 0/51 (0%) | 0/51 (0%) |
| Gabapentin 1200 mg Single Dose | 0/52 (0%) | 0/52 (0%) | 2/52 (3.8%) |
| Gabapentin 600 mg and Oxycodone HCl 20 mg | 0/52 (0%) | 0/52 (0%) | 4/52 (7.7%) |
| Gabapentin 1200 mg and Oxycodone HCl 20 mg | 0/52 (0%) | 0/52 (0%) | 2/52 (3.8%) |
| Event | Placebo | Oxycodone HCl 20 mg Single Dose | Gabapentin 600 mg Single Dose | Gabapentin 1200 mg Single Dose | Gabapentin 600 mg and Oxycodone HCl 20 mg | Gabapentin 1200 mg and Oxycodone HCl 20 mg |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/53 | 4/52 | 0/51 | 0/52 | 4/52 | 2/52 |
| VomitingGastrointestinal disorders | 0/53 | 0/52 | 0/51 | 1/52 | 0/52 | 0/52 |
| Muscle strainInjury, poisoning and procedural complications | 0/53 | 0/52 | 0/51 | 1/52 | 0/52 | 0/52 |
The randomized population included all participants who were randomized to a treatment sequence in the Treatment Phase.
| Age, Continuous(Years) | Randomized Population |
|---|---|
| Mean | 33.3 ± 8.41 |
| Sex: Female, Male(Participants) | Randomized Population |
|---|---|
| Female | 16 |
| Male | 38 |
| Ethnicity (NIH/OMB)(Participants) | Randomized Population |
|---|---|
| Hispanic or Latino | 12 |
| Not Hispanic or Latino | 42 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Randomized Population |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 35 |
| White | 13 |
| More than one race | 4 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Randomized Population |
|---|---|
| United States | 54 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Dec 2021, 8 months.
Results were first posted in Aug 2023, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin